For the social worker running back-to-back sessions at a community mental health clinic, the day rarely ends when the last client leaves. It ends two or three hours later, after the progress notes are written, the billing codes are entered, and the compliance checklists are signed off. That after-hours documentation load is one of the most cited drivers of clinician burnout in behavioral health, a workforce already stretched thin against rising demand for treatment of depression, anxiety, serious mental illness, and substance use disorder. Eleos Health, a Waltham, Massachusetts company founded in 2020, is betting that an AI scribe purpose-built for therapy sessions can give those clinicians their evenings back, and in doing so, expand the number of patients each provider can responsibly carry.
The company announced a $60 million Series C round, bringing total disclosed funding across its Series A, B, and C to roughly $120 million [Eleos Health]. The investor syndicate includes Greenfield Partners, F-Prime Capital, Eight Roads Ventures, Menlo Ventures, ION, Lool Ventures, Arkin Digital Health, and Samsung NEXT. Eleos sells into community behavioral health organizations, substance use treatment providers, and increasingly into adjacent post-acute settings. Its core product listens to a therapy or counseling session with consent, then generates a structured progress note, surfaces evidence-based intervention tags, and now, with the recently launched Eleos Compliance product, scans every eligible note daily for documentation gaps and regulatory risk [Eleos Health].
The bet
The wedge is narrow on purpose. General-purpose ambient scribes from larger health-tech vendors are aimed mostly at primary care and specialty medicine, where the visit structure, vocabulary, and billing logic differ sharply from a 50-minute therapy hour. Eleos has trained its models on real session data from community-based behavioral health clinics, and it uses Retrieval-Augmented Generation to ground outputs in the actual session transcript rather than the model's general knowledge, an approach the company says reduces the kind of confident-sounding fabrications that would be unacceptable in a clinical record [Eleos Health]. The company reports serving 30,000 clinicians and says its tools have contributed to a tripling of individuals cared for by its customers, surpassing one million people [Healthcare Trailblazers Podcast; LinkedIn].
The standard of care in behavioral health documentation today is, in most clinics, still manual. A clinician finishes a session, opens the electronic health record, and types a SOAP or DAP note from memory, often hours later. Compliance review is sample-based: a quality team might audit five percent of notes per quarter against Medicaid, commercial payer, and state licensing requirements. Denials, clawbacks, and audit findings often surface months after the fact, when remediation is expensive. Against that baseline, Eleos is pitching continuous, automated review of every note, every day, which the company describes as a 20x increase in note review volume over the manual approach [Eleos Health].
Why it could be big
Behavioral health sits at an unusual intersection of regulatory tailwinds and workforce shortage. Medicaid expansion of behavioral health benefits, the federal push on mental health parity, and the growing share of value-based contracts in the category all reward providers who can document outcomes rigorously and bill cleanly. At the same time, the U.S. faces a documented shortfall of licensed therapists, psychiatrists, and substance use counselors. Any tool that credibly returns clinical hours to a clinician without compromising the chart is selling into a market with structural willingness to pay.
The investor base reflects that thesis. F-Prime and Eight Roads bring deep healthcare specialty bench strength; Menlo and Samsung NEXT bring scaling experience in enterprise software; Arkin Digital Health is specifically focused on the category. Eleos has also locked in distribution-level partnerships that matter more than any single hospital logo: a tie-up with the Rehabilitation and Community Providers Association (RCPA), whose members serve over one million individuals annually [Eleos Health], an integration partnership with Streamline Healthcare Solutions, an EHR widely used in community behavioral health [Eleos Health, 2025], and a reported engagement with CalMHSA covering AI in behavioral health across California [Tracxn, 2026].
Series A 2022 | 20 | $M
Series B 2023 | 40 | $M
Series C | 60 | $M
The team and traction
Eleos was co-founded by Alon Joffe, who serves as CEO, alongside Alon Rabinovich as CTO and Dror Zaide as CRO, with Karan Jain also named as a co-founder [Crunchbase; LinkedIn; Preqin]. Joffe served six years in an elite combat search and rescue unit of the Israeli Air Force before studying at IDC Herzliya [Healthcare Reimagined Podcast; LinkedIn], and was profiled by Ctech for balancing IDF reserve duty with running the company [Ctech]. Zaide trained at MIT Sloan [LinkedIn]. The company reports that its customers have seen administrative time cut by more than half and that Eleos automatically generates roughly half of required documentation [Eleos Health, Bloomberg Professional Services]. Across more than 30 partnerships, Eleos cites 260 days of total documentation time saved [Eleos Health]. The company is hiring across multiple roles on Greenhouse and Workable, and is publicly expanding into home health, palliative, and hospice, three adjacent settings where the documentation burden looks structurally similar to behavioral health [Eleos Health].
The honest counterfactual
The most credible pressure on Eleos is competitive. Twofold and Upheal are chasing the same behavioral health scribe category, and the broader ambient-AI scribe market includes well-funded generalists who could move down-market into therapy workflows. Bears will point out that the headline efficiency claims, including the 20x review volume figure and the 80 percent reduction in administrative burden, originate from the company and its customer case studies rather than peer-reviewed evaluations [Eleos Health; Bloomberg Professional Services]. The bull answer is that Eleos has built distribution moats that are harder to replicate than model quality: an EHR integration with Streamline, a state-level engagement in California, and an association partnership with RCPA all put the product in front of clinicians inside their existing workflow, which is typically where behavioral health software wins or loses. The Compliance product also extends the wedge beyond scribing into a category, automated regulatory review, where general scribes do not yet play.
What to watch
Over the next 12 months, the questions worth tracking are concrete. Does Eleos publish, or partner with an academic group to publish, peer-reviewed evidence on documentation accuracy and clinician burnout outcomes, the kind of evidence that state Medicaid agencies increasingly want before endorsing AI tools? Does the home health and hospice expansion produce a named anchor customer? And does the Compliance product, still early in its rollout, convert from a feature into a standalone line item on enterprise contracts? The Series C gives the company runway to answer all three.
Patient population: adults and adolescents receiving outpatient treatment for mental health and substance use disorders, primarily through community behavioral health organizations in the United States. Regulatory context: Eleos operates as clinical workflow software rather than a regulated medical device, which keeps it outside the FDA's Software as a Medical Device pathway for now, but squarely inside HIPAA, 42 CFR Part 2 for substance use records, and state Medicaid documentation rules. Worth watching closely.
Pulse Raman, Health and Bio Correspondent, Startuply